Patent Prosecution
Duty of Candor
Every inventor, attorney, and substantively involved party must disclose material prior art to the USPTO. Withholding material information with deceptive intent renders the entire patent unenforceable.
What is the duty of candor and who has it?
The duty of candor is a legal obligation under 37 C.F.R. § 1.56 to disclose to the USPTO all information known to be material to the patentability of the claimed invention.
Statutory Basis
- The duty is codified in 37 C.F.R. § 1.56
- It is grounded in the equitable principle that the patent applicant must deal fairly with the USPTO, which must rely on the applicant's representations because it cannot independently investigate all facts
Who has the Duty
- (a) each inventor named in the application
- (b) each attorney or agent who prepares or prosecutes the application
- (c) every other person who is substantively involved in the preparation or prosecution of the application AND who is associated with the inventor, the applicant, or the assignee
- 'substantively involved' includes people who: review the application, provide prior art, advise on claim scope, or participate in prosecution decisions
Who Does not Have the Duty
- People who merely provide financial or administrative support without substantive technical or legal input
- Third parties who provide prior art to the applicant without being substantively involved in prosecution
Scope. The duty applies throughout the prosecution of the application — from filing until the application is granted or abandoned
Material Information
- The duty requires disclosure of information that the individual KNOWS to be material
- There is no duty to search for material information
Information Disclosure Statements (IDS)
- The standard mechanism for fulfilling the duty of candor
- An IDS lists prior art and other material information for the examiner to consider.
What information is 'material' to patentability and must be disclosed?
Materiality determines what must be disclosed — the standard has evolved with the Therasense decision: CURRENT STANDARD — THERASENSE (Fed. Cir. 2011, en banc): information is material if the USPTO would not have allowed the claim(s) BUT FOR the withheld reference or misrepresentation; this is the 'but-for' materiality standard; it requires that the information must establish a prima facie case of unpatentability — if disclosed, the examiner would have rejected the claim(s);.
Pre-therasense Standard
- The previous 'reasonable examiner' standard held that information was material if there was a substantial likelihood that a reasonable examiner would consider it important in deciding whether to allow the claims
- This was a broader standard that the Federal Circuit found led to overcrowding of IDS disclosures
Therasense Exception — Affirmative Egregious Misconduct. Even under the but-for standard, if an applicant engages in 'affirmative egregious misconduct' (e.g., filing a false affidavit), the misconduct is material regardless of whether the claims would have been rejected
Examples of Material Information
- (1) a prior art reference that anticipates or renders obvious at least one claim
- (2) contradictory data known to the inventor that undermines a patentability argument made to the examiner
- (3) a prior art reference identified during a related litigation
- (4) a rejection of a related foreign application based on specific prior art
- (5) a claim construction by another court that contradicts the applicant's claim construction argument
Non-material Information
- Cumulative information (prior art already cited by the examiner)
- Information only tangentially related to the claims.
What is an information disclosure statement (IDS) and how is it filed?
An IDS is the USPTO form for disclosing material information, fulfilling the duty of candor.
Form and Content
- USPTO Form PTO/SB/08 (patent) or PTO/SB/08a/08b (non-patent literature)
- The IDS lists: (a) US patent documents (number and issue date)
- (b) US patent application publications
- (c) foreign patent documents
- (d) non-patent literature (journal articles, conference papers, product manuals)
Copies Required
- Applicant must submit copies of each cited document UNLESS: (a) the reference is a US patent or US published application (USPTO has its own copies)
- (b) the reference was previously considered by the USPTO in a related application and applicant states where
Timeliness — When Ids is Free
- An IDS filed before the earlier of: (a) the mailing date of a first office action on the merits
- Or (b) three months after the application filing date
- No fee required
Timeliness — After First Office Action
- IDS filed after the first office action but before (a) the mailing of a notice of allowance OR (b) a statement that the claims have been allowed
- Requires a certification that each item was first cited or received after the filing of the first office action
Timeliness — After Notice of Allowance
- An IDS may still be filed after a notice of allowance, but ONLY with: (a) payment of additional fee ($200 large entity)
- AND (b) certification that the information was first learned less than 3 months before filing
Without Proper Certification/fee
- An IDS filed outside the timeliness windows without the required certification or fee is NOT considered by the USPTO
- The duty may not be satisfied.
What happens when the duty of candor is violated — what is inequitable conduct?
Violation of the duty of candor with deceptive intent constitutes inequitable conduct, which renders the entire patent unenforceable: INEQUITABLE CONDUCT ELEMENTS (post-Therasense).
(1) Materiality. The withheld information or misrepresentation is material (but-for standard — patent would not have issued with the information)
(2) Deceptive Intent
- The person who made the disclosure decision did so with specific intent to deceive the USPTO
- Both elements must be proven by CLEAR AND CONVINCING evidence
Therasense Tightened Intent Standard
- The Federal Circuit in Therasense eliminated the 'sliding scale' where a low materiality could be offset by high intent and vice versa
- Both elements must independently meet their thresholds
- 'should have known' or gross negligence is insufficient — actual specific intent to deceive is required
Entire Patent Unenforceable
- Unlike invalidity (which can affect specific claims), inequitable conduct renders the ENTIRE PATENT unenforceable
- Even valid, non-obvious claims become unenforceable
Infectious Unenforceability. Related patents that share the inequitable conduct (same applicant, same attorney, same withheld prior art) may also be rendered unenforceable under the infectious unenforceability doctrine
Defense Strategy
- Defendants in patent infringement cases assert inequitable conduct as an equitable defense
- It requires a bench trial (not a jury)
- It is determined by the judge
Duty Satisfied by Ids
- Filing an IDS that fully discloses the material information, even if the examiner ultimately allows the claims, satisfies the duty
- The examiner's decision to allow after considering the information is the examiner's responsibility.
Related guides